Abstract
We prospectively evaluated docetaxel (100 mg/m2) with g-csf (10 μg/kg s.c., daily) for mobilization efficiency in 26 patients with breast cancer. the minimum target yield was >4.5 × 106 CD34+ cells/kg (optimum = 9 × 106/kg), sufficient to support the subsequent three cycles of high-dose therapy (HDT). The peak days for peripheral blood (PB) CD34+ cells were day 8 and day 9. Seven collections began on day 7, 16 on day 8 and three on day 9. The median peripheral blood progenitor cell (PBPC) CD34+ cell content ranged from 1.2 to 5.9 × 106/kg per day during days 7 to 11 with a median CD34+ content of the total 72 PBPC collections of 3.4 × 106/kg (0.07–15.6). Fifteen patients obtained a PBPC collection exceeding 5 × 106/kg on a single day of collection. Following a median 3 days collection for each patient (range 2–4), the median total CD34+ for all individual sets of collections was 9.7 × 106/kg (range 1.0–28.4). We were able to achieve the minimum CD34+ cell target yield in 22 of 26 patients with one cycle of mobilisation chemotherapy and in two of these patients a second collection yielded sufficient cells. twenty-two patients have subsequently received repetitive hdt and pbpc transplantation with 57 cycles of hdt having been delivered. for all 57 cycles, the median time to absolute neutrophil count (anc) >0.5 × 109/l and 1.0 × 109/l was 10 days (range 8–22) and 11 days (range 8–23), respectively. The median time to platelets greater than 20 × 109/l, 50 × 109/l and 100 × 109/l was 13 days (range 11–23), 17 days (range 12–53) and 23 days (range 18–70), respectively. We conclude that docetaxel with G-CSF effectively mobilises PBPCs with apheresis needing to be commenced approximately 8 days after docetaxel administration. Bone Marrow Transplantation (2000) 26, 483–487.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hyrniuk W, Bush H . The importance of dose intensity in chemotherapy of metastatic breast cancer J Clin Oncol 1984 2: 1281–1288
Siu LL, Tannock IF . Chemotherapy dose escalation: case unproven J Clin Oncol 1997 15: 2765–2768
Sledge GW, Antman KH . Progress in chemotherapy for metastatic breast cancer Semin Oncol 1996 19: 317–332
Antman KH, Rowlings PA, Vaughan WP et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America J Clin Oncol 1997 15: 1870–1879
Peters WP, Jones RB, Vredenburgh J et al. A large, prospective, randomized trial of high-dose combination alkylating agents (CPB) with autologous cellular support (ABMS) as consolidation for patients with metastatic breast cancer achieving a complete remission after intensive doxorubicin-based induction therapy (AFM) Proc Am Soc Clin Oncol 1996 15: 121–149
Bezwoda WR, Seymour L, Dansey RD . High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial J Clin Oncol 1995 13: 2483–2489
Stadtmauer EA, O'Neill LJ, Goldstein LJ et al. Conventional-dose chemotherapy compared to high-dose chemotherapy plus autologous hematopoietic stem cell transplantation for metastatic breat cancer New Engl J Med 2000 342: 1069–1076
Lotz JP, Cure H, Janvier M et al. High-dose chemotherapy with hematopoietic stem cells transplantation for metastatic breast cancer: results of the French protocol PEGASE 04 Proc Am Soc Clin Oncol 1999 18: 43a 161
Prince HM, Millward MJ, Rischin D et al. Repetitive high-dose therapy with ifosfamide, thiotepa and paclitaxel with blood cell support for metastatic breast cancer: results of phase I study Ann Oncol 1999 10: 479–481
Prince HM, Millward MJ, Blakey D et al. Repetitive high-dose therapy with peripheral blood progenitor support for metastatic and locally advanced breast cancer Autologous Blood and Marrow Transplantation: Proceedings of the Ninth International Symposium, Arlington, Texas Charlottesville, Virginia: Carden Jennings Publishing 1999 303–331
Prince HM, Bertoncello I, Millward M et al. Isolex 300i CD34-selected blood cells are capable of supporting multiple cycles of high-dose chemotherapy Exp Hematol 1998 26: 702–768
Hudis C, Seidman A, Crown JPA et al. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer J Clin Oncol 1996 14: 58–65
Chan S, Friedrichs K, Noel D et al. A randomized phase III study of Taxotere versus doxorubicin in patients with metastatic breast cancer who have failed an alkylating containing regimen: preliminary results Proc Am Soc Clin Oncol 1997 16: 154a–540
Valero V, Holmes FA, Walters RS et al. Phase II trial of docetaxel: a new highly effective antineoplastic agent in the management of patients with anthracycline resistant metastatic breast cancer J Clin Oncol 1995 13: 2886–2894
Ravdin PM, Burris HA, Cook G . Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer J Clin Oncol 1995 13: 2879–2885
Guastalla JP, Bonneterre J, Fumoleau P et al. A phase II trial of docetaxel in patients with anthracycline resistant metastatic breast cancer Eur J Cancer 1995 31A: (Suppl.5) 31A–348
Chapple P, Prince HM, Quinn M et al. Peripheral blood CD34-positive cell count reliably predicts autograft yield Bone Marrow Transplant 1998 22: 125–130
Sutherland DR, Anderson L, Keeney M et al. The ISHAGE guidelines for CD34+ cell determination by flow cytometry J Hematother 1996 5: 213–226
Prince HM, Rischin D, Tonor OC et al. Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study Bone Marrow Transplant 2000 (in press)
Wilke R, Brettell M, Prince HM et al. Comparison of COBE Spectra software version 4.7 and version 6.0 Auto PBSC Program J Clin Apheresis 1999 14: 26–30
Prince HM, Gardyn J, Millward MJ et al. Ifosfamide in combination with paclitaxel or doxorubicin: regimens which effectively mobilize peripheral blood progenitor cells while demonstrating anti-tumor activity in patients with metastatic breast cancer Bone Marrow Transplant 1999 23: 427–435
Weaver CH, Schwartzberg LS, Zhen B et al. Mobilization of peripheral blood stem cells with docetaxel and cyclophosphamide (CY) in patients with metastatic breast cancer: a randomized trial of 3 vs 4g/m2 of CY Bone Marrow Transplant 1999 23: 421–425
Corsini C, Peccatori F, Mancuso P et al. Epirubicin and docetaxel is a very effective regimen for peripheral blood progenitor cells mobilization Exp Hematol 1998 26: 784 No.372
Goss G, Szer J, Grigg A . Intermediate dose cyclophosphamide combined with a growth factor is a safe and effective regimen for mobilisation of peripheral blood progenitor cells Aust NZ J Med 1996 26: 411–413
Prince HM, Imrie K, Keating A et al. Cyclophosphamide, adriamycin, 5 fluorouracil and G-CSF mobilization achieves high peripheral blood progenitor cell yield which can support multiple cycles of high-dose chemotherapy Blood 1995 86: (Suppl.1) 404a 1602
Socinski MA, Cannistra SA, Elias A et al. Granulocyte–macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man Lancet 1988 ii: 1194–1198
McQuaker IG, Haynes AP, Stainer C et al. Stem cell mobilization in resistant or relapsed lymphoma: superior yield of progenitor cells following a salvage regimen comprising ifosphamide, etoposide and epirubicin compared to intermediate-dose cyclophosphamide Br J Haematol 1997 98: 228–233
Viens P, Gravis G, Genre D et al. High-dose sequential chemotherapy with stem cell support for non-metastatic breast cancer Bone Marrow Transplant 1997 20: 199–203
Acknowledgements
We wish to thank Rhone Poulenc Rhorer, Australia and Amgen, Australia for their generous support of this study, the research nurses, apheresis nurses and nursing staff on the Haematology and Day Wards at Peter MacCallum Cancer Institute for commitment, dedication and expert patient care.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Prince, H., Toner, G., Seymour, J. et al. Docetaxel effectively mobilizes peripheral blood CD34+ cells. Bone Marrow Transplant 26, 483–487 (2000). https://doi.org/10.1038/sj.bmt.1702540
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1702540
Keywords
This article is cited by
-
Mobilization of peripheral blood stem cells using regimen combining docetaxel with granulocyte colony-stimulating factor in breast cancer patients
Chinese Journal of Cancer Research (2011)
-
Severe interstitial pneumonitis following high-dose cyclophosphamide, thiotepa and docetaxel: two case reports and a review of the literature
Bone Marrow Transplantation (2001)
-
A phase II trial of docetaxel for peripheral blood stem cell mobilization for patients with breast cancer and ovarian cancer
Bone Marrow Transplantation (2001)
-
Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study
Bone Marrow Transplantation (2000)